NB200-582 TAG72 antibody
see related secondary antibodiessee all 18 TAG72 products
0.5 ml / US$ 485 no delivery possible
Quick Overview
Mouse anti TAG72 B72.3
Synonyms
anti-CA 72-4 antibody; Anti-TAG 72 antibody; Anti-Tumor associated Glycoprotein 72 antibody,
Product Description
Mouse anti TAG72 B72.3. Product is tested for Flow cytometry ( F ), Immunoprecipitation ( IP ), Western blot / Immunoblot ( WB ), Frozen sections ( C )
Properties
| Applications | Flow cytometry ( F ), Immunoprecipitation ( IP ), Western blot / Immunoblot ( WB ), Frozen sections ( C ) |
| Reactivity | Human ( Hu ), Rat ( Rt ) |
| Host | Mouse |
| Isotype | IgG1 |
| Clone | B72.3 |
| Catalog Number | NB200-582 |
| Quantity | 0.5 ml |
| Price | US$ 485 no delivery possible |
| Delivery | Not USA/Canada |
| Manufacturer | Novus Biologicals Inc. |
| Datasheet |  http://www.novusbio.com/d ... |
Datasheet Extract
| Mouse Monoclonal anti-TAG72 (B72.3) | |
| Alternate names | anti-CA 72-4 antibody |
| Background | Tumor-associated glycoprotein (TAG-72) is an oncofetal antigen with properties of a mucin. About 60% of carcinoma patients express TAG-72 in their sera. Majority of human adenocarcinomas including colorectal, pancreatic, gastric, ovarian, endometrial, mammary, and non-small cell lung cancer display some cell populations that are positive for Ab-1 staining. Weak or no reactivity has been observed with most cell types of normal adult tissue excepting the secretory endometrium. Ab-1 is reportedly useful in distinguishing pulmonary adenocarcinomas (B72.3+) from pleural mesotheliomas (B72.3-). |
| Immunogen | Membrane-enriched fraction of a human breast carcinoma liver metastasis |
| Format | BufferSystem: 10mM PBS, pH 7.4 with 0.2% BSA and 0.09% sodium azide |
| Applications | FACS, IP, WB, IHC |
| Specificity | Species: Cross-reacts with Human, Rat, Bovine, Dog and Hamster.Not yet tested in other species. |
| Storage | Store at 4C. Do not freeze. |
| References | 1. Clemo FA; DeNicola DB; Delaney LJ. Immunohistochemical evaluation of canine carcinomas with monoclonal antibody B72.3. Veterinary Pathology, 1993,30(2):140-5. 2. Salem RR; Wolf BC; Sears HF; Lavin PT; Ravikumar TS; DeCoste D; D'Emilia JC; Herlyn M; Schlom J; Gottlieb LS; et al. Expression of colorectal carcinoma-associated antigens in colonic polyps. Journal of Surgical Research, 1993,55(3):249-55. 3. Sirgi KE; Wick MR; Swanson PE. B72.3 and CD34 immunoreactivity in malignant epithelioid soft tissue tumors. Adjuncts in the recognition of endothelial neoplasms. American Journal of Surgical Pathology, 1993, 17(2):179-85. 4. Brandwein MS; Huvos AG; Patil J; Jagirdar J. Tumorassociated glycoprotein distribution detected by monoclonal antibody B72.3 in salivary neoplasia. Cancer, 1992, 69(11):2623-30. 5. Soomro S; Shousha S. Monoclonal antibody B72.3 immunostaining of breast carcinoma. Patterns of staining and relationship to mucin content and GCDFP-15 reactivity. Archives of Pathology and Laboratory Medicine, 1992, 116(1):32-5. 6. Cajigas HE; Fariza E; Scully RE; Thor AD. Enhancement of tumor-associated glycoprotein-72 antigen expression in hormone-related ovarian serous borderline tumors. Cancer, 1991, 68:348-54. 7. Guadagni F; Roselli M; Amato T; Cosimelli M; Mannella E; Perri P; Abbolito MR; Cavaliere R; Colcher D; Greiner JW; et al. Tumor-associated glycoprotein-72 serum levels complement carcinoembryonic antigen levels in monitoring patients with gastrointestinal carcinoma. A longitudinal study. Cancer, 1991, 68(11):2443-50. 8. Guadagni F; Roselli M; Amato T; Cosimelli M; Mannella E; Tedesco M; Grassi A; Casale V; Cavaliere F; Greiner JW; et al. Clinical evaluation of serum tumor-associated glycoprotein-72 as a novel tumor marker for colorectal cancer patients. Journal of Surgical Oncology. Supplement, 1991, 2:16-20. 9. Loy TS; Springer D; Chapman RK; Diaz-Arias AA; Bulatao IS; Bickel JT. Lack of specificity of monoclonal antibody B72.3 in distinguishing chronic pancreatitis from pancreatic adenocarcinoma [see comments]. Am Journal of Clinical Pathology, 1991, 96:684-8. 10. Prey MU; Bedrossian CW; Masood S. The value of monoclonal antibody B72.3 for the diagnosis of breast carcinoma: experience with the first commercially available source. Human Pathology, 1991, 22(6):598-602. 11. Sawady J; Friedman MI; Katzin WE; Mendelsohn G. Role of the transitional mucosa of the colon in differentiating primary adenocarcinoma from carcinomas metastatic to the colon. An immunohistochemical study. American Journal of Surgical Pathology, 1991, 15(2):136-44. 12. Battista P; Muraro R; Mammarella S; Curia MC; Colasante A; Rosini S; Lesti G; Sacco R; French D; Frati L; et al. Complementary reactivities of anti-carcinoembryonic antigen and antitumor-associated glycoprotein 72 monoclonal antibodies in lung carcinomas. Cancer Research, 1990, 50(21):6987-94. 13. Berchuck A; Olt GJ; Soisson AP; Kamel A; Soper JT; Boyer CM; Clarke-Pearson DL; Leslie DS; Bast RC Jr. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. American Journal of Obstetrics and Gynecology, 1990, 162(4):883-8. 14. Mazur MT; Shultz JJ. Prostatic adenocarcinoma. Evaluation of immunoreactivity to monoclonal antibody B72.3. American Journal of Clinical Pathology, 1990, 93(4):466-70. 15. Soomro S; Shousha S. Monoclonal antibody B72.3 in benign breast lesions. Journal of Clinical Pathology, 1990, 43(12):1026-8. 16. Listrom MB; Little JV; McKinley M; Fenoglio-Preiser CM. Immunoreactivity of tumor-associated glycoprotein (TAG-72) in normal, hyperplastic, and neoplastic colon. Human Pathology, 1989, 20(10):994-1000. 17. Ordonez NG. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J of Surgical Pathology, 1989, 13:276-91. 18. Soisson AP; Berchuck A; Lessey BA; Soper JT; Clarke-Pearson DL; McCarty KS Jr; Bast RC Jr. Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. American Journal of Obstetrics and Gynecology, 1989, 161(5):1258-63. 19. Takiyama Y; Tempero MA; Takasaki H; Onda M; Tsuchiya R; Buchler M; Ness M; Colcher D; Schlom J; Pour PM. Reactivity of CO17-1A and B72.3 in benign and malignant pancreatic diseases. Human Pathology, 1989, 20(9):832-8. 20. Tempero M; Takasaki H; Uchida E; Takiyama Y; Colcher D; Metzgar RS; Pour PM. Co-expression of CA 19-9, DUPAN-2, CA 125, and TAG-72 in pancreatic adenocarcinoma. American Journal of Surgical Pathology, 1989, 13 Suppl 1:89-95. 21. Thor A; Itzkowitz SH; Schlom J; Kim YS; Hanauer S. Tumor-associated glycoprotein (TAG-72) expression in ulcerative colitis. International Journal of Cancer, 1989, 43(5):810-5. 22. Wolf BC; D'Emilia JC; Salem RR; DeCoste D; Sears HF; Gottlieb LS; Steele GD Jr. Detection of the tumor-associated glycoprotein antigen (TAG-72) in premalignant lesions of the colon. Journal of the National Cancer Institute, 1989, 81(24):1913-7. 23. Xu M; Real FX; Welt S; Schussler MH; Oettgen HF; Old LJ. Expression of TAG-72 in normal colon, transitional mucosa, and colon cancer. International Journal of Cancer, 1989, 44(6):985-9. 24. Stanick D; Schuss A; Mishriki Y; Chao S; Thor A; Lundy J. Reactivity of the monoclonal antibody B72.3 with fetal antigen: correlation with expression of TAG-72 in human carcinomas. Cancer Investigation, 1988, 6(3):279-87. 25. Takasaki H; Tempero MA; Uchida E; Buchler M; Ness MJ; Burnett DA; Metzgar RS; Colcher D; Schlom J; Pour PM. Comparative studies on the expression of tumor-associated glycoprotein (TAG-72), CA 19-9 and DU-PAN-2 in normal, benign and malignant pancreatic tissue. International Journal of Cancer, 1988, 42(5):681-6. 26. Ohuchi N; Simpson JF; Colcher D; Schlom J. Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas. International Journal of Cancer, 1987, 40(6):726-33. 27. Thor A; Viglione MJ; Muraro R; Ohuchi N; Schlom J; Gorstein F. Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissues. International Journal of Gynecological Pathology, 1987, 6(3):235-47. 28. Johnson VG; Schlom J; Paterson AJ; Bennett J; Magnani JL; Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Research, 1986, 46(2):850-7. 29. Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J. Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens. Human Pathology, 1986, 17(5):501-13. 30. Johnston WW; Szpak CA; Thor A; Schlom J. Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3. Cancer Research, 1986, 46:6462-70. 31. Lottich SC; Szpak CA; Johnston WW; Thor A; Schlom J. Phenotypic heterogeneity of a tumor-associated antigen in adeno-carcinomas of the colon and their metastases as demonstrated by monoclonal antibody B72.3. Cancer Investigation,1986,4:387-95. 32. Ohuchi N; Thor A; Nose M; Fujita J; Kyogoku M; Schlom J. Tumor-associated glycoprotein (TAG-72) detected in adenocarcinomas and benign lesions of the stomach. International Journal of Cancer, 1986, 38(5):643-50. 33. Paterson AJ; Schlom J; Sears HF; Bennett J; Colcher D. A radioimmunoassay for the detection of a human tumorassociated glycoprotein (TAG-72) using monoclonal antibody B72.3. International Journal of Cancer, 1986, 37(5):659-66. 34. Thor A; Gorstein F; Ohuchi N; Szpak CA; Johnston WW; Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. Journal of the National Cancer Institute, 1986, 76(6):995-1006. 35. Thor A; Ohuchi N; Szpak CA; Johnston WW; Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Research, 1986, 46(6):3118-24. 36. Lottich SC; Johnston WW; Szpak CA; Delong ER; Thor A; Schlom J. Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions. Breast Cancer Research and Treatment, 1985, 6(1):49-56. 1. Myers RB; et al. J Urol, 1994, 152(1):243-6. 2. Roa RA; et al. Laryngoscope, 1994, 104:304-8. 3. Brown RW; et al. Human Pathol, 1993, 24:347-54. |
14 Secondary Antibodies
| Catalog No. | Name / Host | Presentation | Reactivity | ||||
|---|---|---|---|---|---|---|---|
| R1253B | Mouse IgG (H&L) | ||||||
| Rabbit | Biotin | 2 mg / US$ 305 | |||||
| R1253F | Mouse IgG (H&L) | ||||||
| Rabbit | FITC | 2 mg / US$ 285 | |||||
| R1253T | Mouse IgG (H&L) | ||||||
| Rabbit | TRITC | 2 mg / US$ 285 | |||||
| R1253TR | Mouse IgG (H&L) | ||||||
| Rabbit | Texas Red | 2 mg / US$ 295 | |||||
| R1253HRP | Mouse IgG (H&L) | ||||||
| Rabbit | HRP | 2 mg / US$ 315 | |||||
| R1253AP | Mouse IgG (H&L) | ||||||
| Rabbit | AP | 1 mg / US$ 325 | |||||
| R1457C2 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy2 | 1 mg / US$ 445 | |||||
| R1457C3 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy3 | 1 mg / US$ 445 | |||||
| R1457C35 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy3.5 | 1 mg / US$ 445 | |||||
| R1457C5 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy5 | 1 mg / US$ 445 | |||||
| R1457C55 | Mouse IgG (H&L) multi-species ads. | ||||||
| Goat | Cy5.5 | 1 mg / US$ 445 | |||||
| R1405R | Mouse IgG (H&L) F(ab')2 Fragment ads. to Bov, Eq, Hu, Rb, Rt, Sh | ||||||
| Goat | PE | 1 ml / US$ 455 | |||||
| R1403R | Mouse IgG (H&L) F(ab')2 Fragment ads. to Hu serum proteins | ||||||
| Rabbit | PE | 1 ml / US$ 455 | |||||
| R1455R | Mouse IgG (H&L) F(ab')2 Fragment multi-species ads. | ||||||
| Donkey | PE | 1 ml / US$ 455 | |||||
Click here to see all secondary antibodies for 'NB200-582 TAG72'.
